Tenaya Therapeutics reported a net loss of $0.12 per share for the fourth quarter of 2025, a 9.1% improvement over the consensus estimate of $0.13 per share and a significant narrowing from the $0.28 per share loss recorded in the same quarter a year earlier.
The company’s full‑year 2025 loss was $90.6 million, or $0.59 per share, compared with a $111.1 million loss ($1.31 per share) in 2024, indicating a steady reduction in overall losses as the business scales its clinical programs.
Cost control measures drove the earnings beat. Research and development expenses fell from $18.7 million in Q4 2024 to $14.8 million in Q4 2025, and from $86.7 million for the full year 2024 to $68.6 million in 2025. General and administrative costs also declined, further tightening the company’s operating profile.
Cash and capital resources remain robust. Tenaya held $56.3 million in cash as of September 30 2025 and raised $55.8 million in net proceeds from a December 2025 equity offering. In addition, a collaboration with Alnylam Pharmaceuticals provides up to $10 million in upfront cash and more than $1.1 billion in milestone payments, extending the company’s runway through the second half of 2027.
The company’s pipeline continues to advance. Gene‑therapy programs TN‑201 and TN‑401 are progressing toward pivotal trials, while the small‑molecule HDAC6 inhibitor TN‑301 is moving forward. CEO Faraz Ali said, "transformative potential of our science" and added, "We are also excited to take modest but important steps to move TN‑301 -- our clinical‑stage, highly selective, small molecule HDAC6 inhibitor -- forward towards patients."
Management remains optimistic about the company’s momentum and regulatory alignment for upcoming trials, and the extended cash runway reduces near‑term financing risk while the company focuses on advancing its clinical programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.